Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk by Vahid Atashgaran et al.
December 2016 | Volume 6 | Article 2671
Review
published: 26 December 2016
doi: 10.3389/fonc.2016.00267
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Gilberto Schwartsmann, 
Universidade Federal do Rio 
Grande do Sul, Brazil
Reviewed by: 
Tamara Louise Kalir, 
Icahn School of Medicine at 
Mount Sinai, USA  
Tomas Reinert, 
Instituto do Cancer Mãe de 
Deus e Instituto DeVita, Brazil
*Correspondence:
Wendy V. Ingman 
wendy.ingman@adelaide.edu.au
Specialty section: 
This article was submitted to 
Women’s Cancer, 
a section of the journal 
Frontiers in Oncology
Received: 31 August 2016
Accepted: 14 December 2016
Published: 26 December 2016
Citation: 
Atashgaran V, Wrin J, Barry SC, 
Dasari P and Ingman WV (2016) 
Dissecting the Biology of 
Menstrual Cycle-Associated 
Breast Cancer Risk. 
Front. Oncol. 6:267. 
doi: 10.3389/fonc.2016.00267
Dissecting the Biology of  
Menstrual Cycle-Associated  
Breast Cancer Risk
Vahid Atashgaran1,2, Joseph Wrin1,2, Simon Charles Barry2,3, Pallave Dasari1,2 and  
Wendy V. Ingman1,2*
1 Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, Adelaide, SA, Australia, 
2 The Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia, 3 Molecular Immunology Laboratory, 
Discipline of Pediatrics, University of Adelaide, North Adelaide, SA, Australia
Fluctuations in circulating estrogen and progesterone across the menstrual cycle lead to 
increased breast cancer susceptibility in women; however, the biological basis for this 
increased risk is not well understood. Estrogen and progesterone have important roles in 
normal mammary gland development, where they direct dynamic interactions among the 
hormonally regulated mammary epithelial, stromal, and immune cell compartments. The 
continuous fluctuations of estrogen and progesterone over a woman’s reproductive life-
time affect the turnover of mammary epithelium, stem cells, and the extracellular matrix, 
as well as regulate the phenotype and function of mammary stromal and immune cells, 
including macrophages and regulatory T cells. Collectively, these events may result in 
genome instability, increase the chance of random genetic mutations, dampen immune 
surveillance, and promote tolerance in the mammary gland, and thereby increase the 
risk of breast cancer initiation. This article reviews the current status of our understand-
ing of the molecular and the cellular changes that occur in the mammary gland across 
the menstrual cycle and how continuous menstrual cycling may increase breast cancer 
susceptibility in women.
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iNTRODUCTiON
The mammary gland is an essential reproductive organ, present in females of all mammalian spe-
cies, which produces milk for both nourishment and immunological protection of newborns. It is 
a unique organ, as the vast majority of mammary gland development occurs postnatally, during 
puberty, pregnancy, and the postpartum period (1). Mammary gland development is highly depend-
ent on the actions of hormones, including estrogen and progesterone, and these endocrine factors 
act locally within the tissue through complex interactions with growth factors and cytokines in 
the mammary microenvironment (2, 3). While there has been much interest in the cellular and 
molecular interactions directing mammary gland development during pregnancy and postpartum 
involution, surprisingly little is understood of the biological mechanisms that promote development 
during the menstrual cycle.
A number of risk factors are associated with breast cancer, including family history of breast 
cancer, increasing age, and high breast density (4). There are also a number of significant risk fac-
tors associated with a woman’s reproductive history, one of which is increased number of years 
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of menstrual cycling. A large meta-analysis demonstrated that 
the period of time between onset and cessation of menstrual 
cycling strongly correlates with increased breast cancer risk in 
women (5). For each year younger a girl commences menstrual 
cycling, there is a 5% increase in lifetime risk of breast cancer. 
Similarly, for each year older at the time of menopause, there 
is a 3.5% increased breast cancer risk (5). Studies on naturally 
postmenopausal women also showed increased breast cancer risk 
in those who had experienced greater than 490 menstrual cycles 
in their lifetime as compared to those with fewer or irregular 
cycles (6). This indicates that fluctuations in ovarian hormones 
associated with menstrual cycling affect breast cancer susceptibil-
ity. However, the biological basis for the link between fluctuations 
in ovarian hormones and increased breast cancer risk is not well 
understood.
The mammary gland consists of a number of different cell 
lineages including epithelial, hematopoietic, endothelial, and 
stromal (7). Epithelial cells are organized in a hierarchical man-
ner of mammary stem cells (MaSCs), mammary progenitor cells, 
and committed mammary epithelial cells, including luminal 
and myoepithelial cells. The majority of human carcinomas 
originate from mammary epithelial cells (8). Immune cells, 
extracellular matrix (ECM), fibroblasts, and endothelial cells 
are all abundant in the stroma of the mammary gland (9), and 
their roles are mediated via a complex network of intracellular 
and extracellular signaling pathways. It is widely accepted that 
mutations in mammary epithelial cells are the initial drivers of 
tumorigenesis. However, what is increasingly appreciated are the 
cell-to-cell interactions between epithelia and the surrounding 
stroma that affect DNA mutation rate, survival of DNA-mutated 
cells, and development of malignancy in the breast. Fluctuations 
in estrogen and progesterone across the menstrual cycle affect 
the abundance and function of mammary epithelial cells, stromal 
immune cells, and the ECM, and these changes are likely to be 
associated with biological mechanisms that cause increased 
breast cancer risk associated with menstrual cycling. The focus of 
this review is to collate current knowledge of the molecular and 
cellular events that occur during hormone-mediated menstrual 
cycling that affect epithelial and stromal cells in the mammary 
gland and how these contribute to increased breast cancer risk 
in women.
BiOLOGiCAL CHANGeS iN THe BReAST 
DURiNG THe MeNSTRUAL CYCLe
The phases of the menstrual cycle in women are regulated by 
fluctuations in the pituitary gland hormones, follicle-stimulating 
hormone and luteinizing hormone, and the ovarian hormones, 
estrogen and progesterone (10). Hormonal fluctuations are cycli-
cal in nature and occur continuously, such that each cycle merges 
into the next. There is also variability in cycle length (22–36 days) 
between different women (11). The majority of the literature on 
menstrual cycle-associated changes in women is consistent with 
mouse literature and suggests that the main proliferative phase is 
the mid-luteal phase of the menstrual cycle, during which time 
circulating progesterone and estrogen are both high and epithelial 
alveolar buds begin to form. The high level of mitotic activity in 
this phase suggests progesterone is associated with a proliferative 
action (12). Conversely, the late luteal phase or the menstruation 
phase could be considered as the regression phase of mammary 
gland epithelia (13). During this time, the newly formed alveolar 
buds undergo apoptosis and tissue remodeling occurs such that 
the mammary gland returns to its basic architecture ready for 
another menstrual cycle (1, 14).
Progesterone appears to be a key hormone in regulation of 
mammary gland development and regression during the cycle. 
A number of animal studies have demonstrated a positive corre-
lation between the percentage of alveolar epithelial buds in the 
mammary gland and the concentration of serum progesterone 
during the ovarian cycle (15–17). Indeed, the highest percentage 
of alveolar epithelia were observed during the diestrus phase 
(mouse equivalent of luteal phase), where the concentration 
of serum progesterone is maximal. Although estrogen exerts 
proliferative effects on mammary epithelial ducts directly via 
estrogen receptors (ERs) (18), it also upregulates the expres-
sion of the progesterone receptor (PR) during the luteal phase 
of the cycle (19). Importantly, progesterone withdrawal is also a 
critical regulator of mammary gland function. Newly developed 
alveolar buds require continuous progesterone signaling and 
undergo apoptosis and tissue remodeling which returns the 
mammary gland to a more basic architecture when progester-
one falls (17).
These cycles of hormone-driven development and regression 
are likely to have a significant impact on breast cancer risk, even 
when breast cancer arises after menopause. Nielsen et  al. (20) 
noted that clinically occult in situ breast carcinomas and atypical 
lesions are frequent in young and middle-aged women; they may 
remain in the non-invasive phase for 15–20  years before they 
develop into invasive breast cancers. In other words, hormone-
regulated cellular events that occur during premenopausal years 
may induce persistent changes in the developmental fate of mam-
mary epithelial cells. Alterations in signal transduction pathways, 
growth factors, and cell cycle regulators (21) associated with these 
clinically occult cancers would increase the lifetime risk of breast 
cancer.
DiReCT eFFeCTS OF OvARiAN 
HORMONeS ON TUMORiGeNeSiS
The roles of estrogen and progesterone in mammary gland 
development have been investigated using mouse models, gene 
expression analysis, and normal human breast tissues. Animal 
studies demonstrate the critical role of estrogen in mammary 
tumorigenesis, as cancer initiation and development can be 
significantly reduced using anti-estrogenic drugs or by perform-
ing oophorectomy (22–24). This is supported in human studies 
wherein early ablation of the ovaries results in regression of 
disseminated breast cancer (25). Furthermore, use of exogenous 
estrogen and progesterone analogs, such as hormone replace-
ment therapy or hormonal oral contraceptives are known to 
increase breast cancer risk in women (26). The primary mecha-
nism through which exogenous and endogenous hormones are 
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implicated in carcinogenesis is through promotion of mammary 
epithelial cell proliferation, which increases the chance of random 
genetic errors (26).
During the menstrual cycle, the highest proliferative rate 
of mammary epithelial cells occurs in the mid-luteal phase, 
as shown in premenopausal women who had highest cellular 
expression levels of proliferative marker Ki67 in the luteal phase 
versus highest expression of quiescent marker p27 in the follicu-
lar phase (27). A number of studies suggest that the mammary 
gland is more susceptible to carcinogenesis when there is higher 
proliferative activity in mammary epithelial cells (24, 28). The 
higher Ki67+ and the lower p27+ cell frequencies were positively 
associated with higher breast cancer risk among premenopausal 
women (27). Higher proliferative activity increases the chance of 
random mutations or DNA lesions (29). If the DNA-damaged 
cell is not repaired immediately, it will be used as a template for 
DNA synthesis in the next proliferative phase of the menstrual 
cycle, which would lead to the accumulation of faulty cells in the 
mammary epithelia. Polymorphisms in DNA repair genes such as 
BRCA2 and XRCC1, which maintain the integrity of the genome, 
can account for this genetic instability and the inability to repair 
DNA-damaged cells (30, 31). This genomic instability is favorable 
for premalignant cells to gain the faulty genotypes that enable 
tumor progression (32).
Although the role of progesterone in breast cancer etiology 
is controversial, it has been hypothesized that progesterone is 
the main driver of breast cancer risk during the menstrual cycle 
(33). More recently, Brisken et  al. (34) proposed that repeated 
activation of PR signaling during the luteal phase may promote 
tumorigenesis in the breast. On the other hand, a recent study 
suggested the anti-mitogenic effects of progesterone, by inhibit-
ing the estrogen-mediated growth of ER-positive tumors in 
human breast explants and cell lines (35). Overall, it seems that 
exposure to ovarian hormones affects cell signaling pathways 
and mammary progenitor cell fate. This leads to higher mitotic 
activity, which in turn may result in increased risk of genome 
instability and random genetic errors in DNA replication.
iMPACT OF MeNSTRUAL  
CYCLiNG ON MaSCs
Mammary stem cells reside within the breast tissue and sup-
port mammary gland morphogenesis during different stages of 
development, such as during pregnancy. These cells are capable 
of self-renewal divisions as well as generating various lineages of 
mammary epithelial cells (36, 37). With the recent advances in 
stem cell biology and the technical frameworks for identification 
of these cells, the concept that cancers originate from stem cells 
and that MaSCs are the targets for transformation has become a 
hot topic in understanding breast cancer risk.
It should be noted that only a small percentage of normal 
mammary epithelial cells express ER and PR, and MaSCs 
lack these hormone receptors. Nevertheless, they are highly 
responsive to and are regulated by estrogen and progesterone via 
paracrine signaling from luminal cells involving receptor activa-
tor of nuclear factor-κB ligand (RANKL), WNT, CXCL12, and 
amphiregulin (38–41). Investigating the phenotypes of MaSCs 
in the mammary gland, particularly during the menstrual cycle, 
can be very challenging due to their rarity and the absence of 
specific markers for identification of these cells (42). Although 
there is evidence suggesting that ovarian hormones regulate the 
fate of MaSCs (7), research on the link between estrogen and 
progesterone and these multi-potent cells during menstrual 
cycling is limited.
In 2009, Graham et  al. (43) reported that progesterone 
increases proliferation of normal human mammary epithelial 
cells by activating DNA replication mechanisms and increas-
ing the number of bipotent progenitor cells. However, recent 
studies by Lombardi et al. (44) implicate another hormone in 
this process. Progesterone induces normal mammary epithelial 
cells to secrete pituitary hormone and growth hormone, and 
subsequently growth hormone increases proliferation of stem 
and progenitor cells in the mammary gland (44). The highest 
levels of serum growth hormone occurs in the luteal phase, 
correlating with the high progesterone levels. Joshi et  al. (7) 
observed that the abundance of MaSCs significantly increases 
during the diestrus phase in cycling mice as well as in ova-
riectomized mice treated with the combination of estradiol and 
progesterone.
It is speculated that the high levels of growth hormone and 
progesterone during the luteal phase expand the numbers and 
proliferation rates of undifferentiated stem cells (44). These hor-
mones may alter the phenotypes of mammary progenitor cells 
and increase the likelihood of transformation of undifferentiated 
cells into malignancy (7). Moreover, progesterone affects both 
symmetric and asymmetric cell division of MaSCs by increasing 
the population of basal and mature mammary epithelial cells 
(7). An imbalance between asymmetric and symmetric stem cell 
divisions can occur when there is deregulation in progesterone-
regulated self-renewal pathways, such as WNT and RANKL 
(45, 46). It may be that repetitive menstrual cycling expands 
the number of undifferentiated MaSCs which are more prone 
to oncogenic hits (39, 44), leading to an increased risk of breast 
cancer.
CHANGeS iN THe iMMUNe 
MiCROeNviRONMeNT DURiNG THe 
MeNSTRUAL CYCLe
Mammary gland development and function depends on dynamic 
interactions between hormonally responsive mammary epithelia 
and the immune microenvironment. Immune cells are closely 
associated with mammary epithelial cells (47) and contribute to a 
number of stages of mammary gland development. Macrophages 
affect development and regression of the mammary gland over 
the course of the cycle, and these alternating roles of macrophages 
may affect menstrual cycle-associated breast cancer risk, particu-
larly during the process of mammary gland regression. Another 
type of immune cell that may affect cancer risk in the mammary 
gland during the menstrual cycle is regulatory T cells (Tregs). 
Although immune cells are known to have an active role in the 
development and function of the mammary gland, it is still not 
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clear whether these cells affect menstrual cycle-associated breast 
cancer risk.
If a DNA mutation occurs, there is still a high chance that the 
immune system will recognize and eliminate the premalignant 
cell. Failure of the immune system to eliminate transformed cells 
throughout life can lead to cancer development. Thus, immune 
surveillance is a critical aspect to protect against tumorigenesis 
and evasion of the immune response against transformed cells 
is a hallmark of cancer (48). Studies on breast tumor micro-
environment demonstrate that Tregs, macrophages, and other 
immune cells have critical roles in the immune evasion abilities 
of the tumor in the breast (49). The abundance and function 
of these cells change over the course of the menstrual cycle, 
potentially opening a window of breast cancer risk at specific 
stages of the cycle.
Fluctuations of estrogen and progesterone during the ovar-
ian cycle influence the abundance, phenotype, and function 
of local macrophages in the mammary gland. Macrophages 
promote the proliferation of epithelial cells and formation of 
alveolar buds when circulating estrogen and progesterone con-
centrations are high and promote alveolar bud regression and 
tissue remodeling as circulating progesterone concentration 
declines (16). These processes of development and regression 
are associated with altered macrophage phenotype, which may 
affect the immune microenvironment in the mammary gland 
(17). The impact of hormone-regulated macrophages on breast 
cancer risk is not known, but may affect protection against 
persistence of DNA-mutated cells and tolerance to transformed 
cells, particularly during mammary gland regression, discussed 
in the next section.
Abundance of Tregs in the human blood correlates with serum 
concentration of estrogen; it increases during the follicular phase 
and decreases during the luteal phase (50). Prieto and Rosenstein 
(51) reported that exogenous estradiol promotes proliferation of 
T cell receptor-activated Tregs isolated from the blood of healthy 
individuals and enhances their suppressive function in vitro. On 
the other hand, progesterone regulates differentiation of naïve 
T cells into immune suppressive Foxp3+ Tregs in fetal cord blood 
and promotes immune tolerance (52). It is noteworthy that Tregs 
must be activated before ovarian hormones can enhance their 
suppressive functions (50, 51). Stimuli that activate Tregs during 
the menstrual cycle are not known; however, infections or altered 
cell signaling pathways may play a role.
Both mammary epithelial cells and immune cells secrete 
cytokines and chemokines, which act as intercellular mediators 
in the generation of immune responses. Induction of mam-
mary epithelial differentiation is accompanied by a switch from 
production of Th1 cytokines (such as TNFA, IFNG, and IL12) 
to Th2 cytokines (such as IL13, IL10, and IL4) by mammary 
epithelial cells (53). Interestingly, progesterone has been shown 
to regulate Th1/Th2 phenotypes in the mammary gland (54) 
and is a potent inducer of Th2 cytokines during pregnancy 
(55). Th1 cytokines are more effective in producing antitumor 
immunity and tumor rejection, whereas Th2 cytokines are 
mostly produced by tumors; they induce alternatively activated 
macrophages and are involved in increasing humoral pro-
tumorigenic responses (56, 57).
On the other hand, estradiol is shown to induce pro-
inflammatory cytokine profile during the estrus phase in mice, 
an effect that was strongly mitigated by progesterone during other 
phases of the cycle (58). This inflammatory milieu may lead to 
tumor development and cancer progression. Thus, it seems that 
fluctuations of estrogen and progesterone can direct the cytokine 
profile of immune cells in the mammary gland. Considering 
the immunosuppressive roles of the immune cells in the tumor 
microenvironment, it is possible that these cells may weaken the 
mammary gland’s capability for immune detection at certain 
stages of the menstrual cycle and potentially affect risk of tumo-
rigenesis in the breast.
iNCReASeD CANCeR SUSCePTiBiLiTY 
DURiNG MAMMARY GLAND 
ReGReSSiON
The ductal and alveolar epithelial structures that form in the 
breast during diestrus in anticipation of pregnancy become 
unnecessary when the cycle progresses. These cells must be 
removed as the breast is remodeled during proestrus to a more 
basic architecture. The onset of apoptosis in mammary epithe-
lium that occurs at the end of the luteal phase is tied to declining 
levels of progesterone (59). A number of animal studies have 
compared the sensitivity of the mammary gland to chemical 
carcinogens such as 9,10-dimethyl-1,2-benzanthracene (DMBA) 
or N-methyl-N-nitrosorea (NMU) between different phases of 
the ovarian cycle. Although there are some conflicting results in 
the literature, the majority reported that young rats exposed to 
chemical carcinogens at proestrus had a higher rate of mammary 
tumor incidence (28, 60, 61). This was accompanied by increased 
number of tumors, as well as shorter tumor latency than those 
rats injected during the metestrus or estrus phase. Proestrus is 
the phase in which circulating estrogen is high, and circulating 
progesterone is declining. This suggests that the phase of the 
cycle associated with mammary gland regression may be more 
susceptible to the initiating factors that lead to cancer than other 
phases of the cycle.
Macrophages are central players in the immunologically silent 
removal of apoptotic cells. Hodson et al. (17) reported differential 
percentage of murine macrophages that express cell-surface 
proteins NKG2D, CD204, and MHCII during different stages 
of the ovarian cycle, regulated by progesterone and estrogen. 
Macrophages present during epithelial proliferation and alveolar 
development during diestrus display a greater predominance of 
an immune surveillance phenotype, characterized by the expres-
sion of the NGK2D marker, associated with the recognition of 
DNA-damaged cells (17). At this stage, they are able to remove 
epithelial cells that have experienced replication errors. Toll-like 
receptors, which recognize danger-associated molecular patterns, 
can also participate in this activity. At proestrus, progesterone 
levels have declined, and this is associated with decreased NKG2D 
and an increase in the expression of antigen presentation receptor 
MHCII and scavenger receptor CD204 on macrophages, which 
have roles in phagocytosis and antigen presentation of dying 
epithelial cells (17, 62). Hence, it is suggested that fluctuations 
5Atashgaran et al. Menstrual Cycle-Associated Breast Cancer Risk
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 267
of macrophage phenotypes over the course of the ovarian cycle 
may regulate their capability to recognize DNA-damaged cells, 
phagocytose, and present antigen to generate adaptive immune 
responses, which may subsequently affect tumor incidence in the 
mammary gland (17).
Previously, it was thought that macrophages only protect the 
tissues from cancer, by phagocytizing the apoptotic cell debris or 
presenting tumor-associated antigens to T cells. However, it is 
now clear that these cells are also involved in breast tumorigen-
esis, progression, and metastasis, depending on their functional 
phenotype (63, 64). Macrophages are highly plastic cells that are 
capable of both anti-tumorigenic and pro-tumorigenic functions 
(56). Macrophage phenotypes and functions are heterogeneous, 
complex in human pathologies, and are activated by various 
stimuli (65). It is possible that hormonal regulations of these 
immune cells during menstrual cycling direct them toward a 
pro-tumorigenic state in which they can assist in the growth of 
potential tumors in the tissue.
Concomitant with the drop in progesterone is the increase 
in the expression and activation of TGFB1. TGFB1 has pleio-
tropic effects in the environment of the involuting mammary 
gland, first by further retarding epithelial cell proliferation and 
second by inducing epithelial apoptosis and causing a shift to 
alternative differentiation in the macrophages infiltrating the 
breast (62,  66). TGFB1 signaling triggers apoptosis through 
members of the Bcl family, leading to activation of caspase 3 
with eventual nuclear condensation and DNA fragmentation 
(67). This process is accompanied by the release of damage-
associated molecular patterns (DAMPs) or “find me” signals 
for immune phagocytes. Secreted DAMPs include ATP and 
lysophosphatidylcholine (68). In addition to DAMPs, apop-
totic cells express the membrane markers phosphatidylserine 
(PS) and calreticulin (CRT). PS is normally found in the cell 
membrane on the cytoplasmic side and extracellular exposure 
is an early event in apoptosis. Calreticulin is found in the endo-
plasmic reticulum where it functions in protein folding and 
calcium retention in the endoplasmic reticulum (69). Apoptosis 
dysregulates calcium localization, leading to the release of CRT 
from the endoplasmic reticulum and its eventual exposure on 
the membrane surface (70). Membrane localization of these two 
molecules act as a signal of abnormal processes within the host 
cell and are also important in the eventual clearance of the cell 
by phagocytes (71, 72).
As apoptosis progresses, membrane blebbing leads to the 
release of exosomes. The membrane integrity deteriorates and 
if the cell is not cleared it will eventually become necrotic. In 
necrosis, the cell membrane ruptures and allows the release of 
pro-inflammatory cytoplasmic contents, such as Il-1 alpha and 
HMGB1 (73). Necrosis in breast tissue is not a desirable outcome, 
especially since this tissue will be exposed to hormone cycling 
repeatedly with attendant proliferation/apoptosis during the full 
extent of a woman’s reproductive life. Macrophages and other 
epithelial cells remove apoptotic cells from the breast before they 
necrose and provoke harmful inflammation. Necrosis attracts 
a variety of immune cells that interact to produce a vigorous 
response that increases the possibility of autoimmunity and 
carcinogenic DNA damage (74).
There is a multiplicity of mechanisms for the removal of 
apoptotic cells, both in terms of the target and the phagocyte. 
This allows for an enhanced flexibility in the host immune sys-
tem and a greater likelihood an apoptotic event will be cleared 
and not allowed to necrose. And the key component discussed 
above involves PS only and does not take into account other 
mechanisms involving lectins, thrombospondin, or ICAM-3 
(68). However, the dynamic and changing immune require-
ments in the breast throughout the menstrual cycle may result in 
mutated cells persisting from one cycle into the next, increasing 
the chance of tolerance of pre-cancerous cells and accumulation 
of further mutations that ultimately result in increased risk of 
cancer.
OTHeR POTeNTiAL CANCeR PATHwAYS
The RANKL belongs to the tumor necrosis factor superfamily and 
acts as a paracrine modulator of progesterone action in the adult 
mouse mammary gland (75). RANKL also plays critical roles in 
progesterone-induced expansion of MaSCs and is implicated in 
increased breast cancer risk associated with high exposure to this 
hormone (76). The mRNA and protein expression of RANKL 
in mammary epithelium is upregulated during the luteal phase 
in normal breast tissues from women at standard risk of breast 
cancer as well as in malignant breast tissue, suggesting a role for 
RANKL in breast cancer initiation (40, 77). Moreover, Brisken 
(78) hypothesized, based on mouse model studies that repeated 
activation of RANKL by progesterone during the luteal phase 
promotes breast carcinogenesis. In short, RANKL is considered 
as a potential target in breast cancer treatment and prevention in 
premenopausal women (79).
Using next-generation whole transcriptome sequencing on 
20 samples of normal human breast epithelium, Pardo et al. (40) 
examined the effects of hormonal fluctuations during menstrual 
cycle on gene expression. There were significant differences in 
the expression of 255 genes between the two phases of the men-
strual cycle, most of which had higher expression in the luteal 
phase compared to the follicular phase. Genes elevated during 
the luteal phase include FOXM1, MYC, BCRA1, and WNT4, and 
are mainly involved in the cell cycle events, such as DNA replica-
tion, DNA damage response, and mitosis. Interestingly, steroid 5 
alpha reductase 1 (SRD5A1) gene, which has a role in catalyzing 
the conversion of progesterone to 5 alpha-pregnenes mitogens 
in situ (80), was highly expressed during the luteal phase. This 
finding suggests that the fate of progesterone metabolism is 
affected during the menstrual cycle. Most of the cell cycle genes, 
which had higher expression in the luteal phase in this study 
are overexpressed in breast cancer samples (40). Hence, it is 
likely that the rise of progesterone during the luteal phase drives 
mitosis, which may increase the likelihood of genome instability 
and mutations in the breast and subsequently increase the risk 
of tumorigenesis.
In 1992, Ferguson and his colleagues noted that molecular 
profile of ECM in the human breast changes during the men-
strual cycle in vivo (81). Alterations in the molecular profile of 
ECM would alter cell signaling and deregulate the behavior of 
stromal cells, which may lead to generation of a tumorigenic 
FiGURe 1 | (A) The concentration of estrogen (green) and progesterone (red) fluctuates during the phases of the menstrual cycle and is associated with 
morphological changes in the cellular components of the mammary gland; shown here in carmine alum-stained mouse mammary gland whole-mount preparations 
(B) [adapted from Ref. (17) with permission]. (C) The follicular phase of the menstrual cycle is characterized by increase in the number of Tregs and proteoglycans 
compared to the luteal phase. In contrast, the luteal phase is characterized by increased numbers of mammary epithelial cells as well as increased abundance of 
macrophages compared to the follicular phase. The phenotype of macrophages in the mammary gland also changes throughout the cycle.
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microenvironment (82). More recently, it was observed that 
gene expression of proteoglycans syndecan-1, syndecan-4, and 
decorin was reduced during the luteal phase in healthy breast 
tissues of parous women (83). Single nucleotide polymorphisms 
in syndeacan-1 are associated with breast cancer susceptibility 
(84, 85). The expression of both Syndeacan-1 and 4 is significantly 
correlated with human carcinoma cell proliferation (86). Reduced 
expression of decorin has also been observed in breast cancer 
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tissues compared with normal tissues (87). It is suggested that 
lower expression of decorin weakens the ECM and is correlated 
with rapid progression, higher recurrence, and poor survival 
rate in breast cancer patients (87, 88). Proteoglycans regulate 
the activity of extracellular regulatory proteins in the ECM and 
interact with growth factors, cytokines, and chemokines (89). 
The direct effects of exogenous hormones on proteoglycans are 
not well studied. However, considering the role of proteoglycans 
in breast carcinomas, it is likely that hormonal regulation of 
these ECM components during the menstrual cycle affects cell 
signaling and triggers cancer pathways in the mammary gland 
microenvironment.
In situ microdialysis on normal human breast tissues revealed 
that the extracellular levels of vascular endothelial growth factor 
(VEGF), which is a potent stimulatory factor in angiogenesis, 
doubled during the luteal phase (90). Angiogenesis and high 
levels of growth factors are important factors for transforma-
tion of normal cells into malignancy (91, 92). Moreover, VEGF 
mRNA expression increases in breast cancer and is induced with 
estrogen and progestins in human breast cancer cell lines (93, 
94). The higher levels of VEGF during the luteal phase suggest 
that there is a proangiogenic microenvironment at this time. 
This reflects the normal capacity of hormone-induced mammary 
gland to stimulate vascular growth. However, as breast cancer is 
an angiogenic-dependent disease (94), this proangiogenic profile 
might provide the essential fuel (i.e., blood supply) for the growth 
of potential tumor cells.
New DiReCTiONS FOR BReAST CANCeR 
DiAGNOSiS AND PReveNTiON iN 
PReMeNOPAUSAL wOMeN
Understanding the biological changes that occur over the 
course of the menstrual cycle could lead to the development 
of new approaches to prevent breast cancer in premenopausal 
women. Studies in rodent species, discussed above, suggest that 
susceptibility to initiating factors that lead to cancer might be 
elevated during specific stages of the cycle. Alcohol consump-
tion increases breast cancer risk, potentially through increasing 
circulating estrogen and enhancing estrogen responsiveness, as 
well as increasing production of reactive oxygen species leading 
to DNA damage (95, 96). Another risk factor for breast cancer is 
exposure to radiation. Medical imaging techniques that employ 
low-dose ionizing radiation, such as computed tomography, 
x-rays, molecular breast imaging, and mammography, can affect 
cancer risk (97, 98). As the susceptibility of the breast to these 
carcinogenic exposures might be altered by menstrual cycle stage 
in premenopausal women, avoidance of exposure to alcohol and 
ionizing radiation at specific stages of the cycle has the potential 
to reduce breast cancer risk.
A better understanding of how immune cell abundance 
and function fluctuates across the menstrual cycle may 
provide us with improved potential to harness the immune 
system to treat and prevent breast cancer. Immunotherapy 
and immunoprevention of cancer can involve immunization 
with a vaccine, passive transfer of tumor-specific antibodies, 
or adoptive transfer of immune cells that kill tumor cells. 
Changes in the types of macrophages in the breast, the cytokine 
microenvironment, and the phenotype of tumor-infiltrating 
lymphocytes across the cycle could affect the efficacy of both 
adaptive and humoral immune responses that recognize and 
eliminate tumorigenic cells (99, 100). Further studies on the 
effect of hormonal fluctuations on immune function could help 
us address such questions as how to improve immune surveil-
lance and break the immunological tolerance induced during 
specific stages of the menstrual cycle.
In addition to potential for breast cancer prevention and 
treatment, research on the effect of menstrual cycle stage on 
gene expression in the breast is critical in improving the utility of 
PCR-based diagnostic and prognostic tests for breast cancer. The 
relative expression of panels of genes, employed in tests such as 
Oncotype DX and Prosigna, classifies tumor subtype and predicts 
risk of disease recurrence, in order to guide treatment decision-
making (101, 102). However, such tests were developed and vali-
dated largely in postmenopausal women, and the utility of these 
tests in premenopausal women might be affected by fluctuating 
estrogen and progesterone at different stages of the menstrual 
cycle (103). Overall, a clearer understanding of the molecular, 
cellular, and immunological changes that occur in the breast 
during the menstrual cycle could be fundamental for improving 
personalized and preventive programs in breast cancer.
CONCLUSiON
Women who undergo early menarche and/or late menopause 
experience higher exposure to estrogen and progesterone, and 
a higher number of cyclical fluctuations of these hormone dur-
ing their life time. Together with the direct effects of estrogen 
and progesterone on cancer initiation, there are a series of 
coordinated events during the menstrual cycle which are regu-
lated by these ovarian hormones which have been implicated 
in increased breast cancer risk. Figure 1 represents a summary 
of the changes in the cellular components of the mammary 
gland during menstrual cycling. The circle of proliferation and 
regression that occurs every month with each menstrual cycle 
affects the fate of MaSCs, which might increase the chance of 
random genetic errors and tumor initiation. An imbalance 
between mammary epithelial cell proliferation and apoptosis 
may provide the ideal conditions for the growth of potential 
tumor cells. In addition, deregulation of stromal components, 
such as ECM, macrophages, and Tregs, may alter the gene 
signaling pathways and tumor suppressor genes in the human 
breast, which might become persistent in some women. In addi-
tion, hormone-regulated immune cells can influence a micro-
environment (e.g., by secreting cytokines and chemokines) in 
which immune surveillance is dampened and the breast is at 
increased risk of oncogenic initiation. Over time, the recurrent 
rise and fall in circulating estrogen and progesterone would 
provide the conditions for altering cell fate, increasing the risk 
of genome instability, and random mutations. It is a significant 
challenge to dissect mechanisms of menstrual cycle-associated 
breast cancer risk; however, the benefit will be that of a greater 
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understanding of breast cancer susceptibility in women and the 
potential for discovery of new cancer biomarkers, indicators 
of prognosis, and therapeutic strategies to treat and prevent 
breast cancer.
AUTHOR CONTRiBUTiONS
All the authors contributed intellectually to the content and writ-
ing of the manuscript.
FUNDiNG
The authors would like to thank the Hospital Research Foundation 
and the National Breast Cancer Foundation for funding our 
research. WI is a THRF Associate Professor and National Breast 
Cancer Foundation Early Career Fellow. PD is supported by 
an Australian Breast Cancer Research Postdoctoral Fellowship. 
VA is supported by University of Adelaide Graduate Research 
Scholarship. JW is supported by Australian Postgraduate Award.
ReFeReNCeS
1. Russo J, Russo IH. Development of the human breast. Maturitas (2004) 
49:2–15. doi:10.1016/j.maturitas.2004.04.011 
2. Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the func-
tional mammary gland: from endocrinology to morphology. J Mammary 
Gland Biol Neoplasia (2002) 7:17–38. doi:10.1023/A:1015766322258 
3. Hennighausen L, Robinson GW. Information networks in the mammary 
gland. Nat Rev Mol Cell Biol (2005) 6:715–25. doi:10.1038/nrm1714 
4. McPherson K, Steel CM, Dixon JM. Breast cancer – epidemiology, 
risk factors, and genetics. BMJ (2000) 321:624–8. doi:10.1136/bmj.321. 
7261.624 
5. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, 
menopause, and breast cancer risk: individual participant meta-analysis, 
including 118 964 women with breast cancer from 117 epidemiological 
studies. Lancet Oncol (2012) 13:1141. doi:10.1016/S1470-2045(12)70425-4 
6. Chavez-MacGregor M, Elias SG, Onland-Moret NC, Van Der Schouw YT, 
Van Gils CH, Monninkhof E, et al. Postmenopausal breast cancer risk and 
cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev 
(2005) 14:799–804. doi:10.1158/1055-9965.EPI-04-0465 
7. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, 
et  al. Progesterone induces adult mammary stem cell expansion. Nature 
(2010) 465:803–7. doi:10.1038/nature09091 
8. Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights 
from cell culture and mouse models. Breast Cancer Res (2005) 7:171–9. 
doi:10.1186/bcr973 
9. Polyak K, Kalluri R. The role of the microenvironment in mammary gland 
development and cancer. Cold Spring Harb Perspect Biol (2010) 2:a003244. 
doi:10.1101/cshperspect.a003244 
10. Sherman BM, Korenman SG. Hormonal characteristics of the human 
menstrual cycle throughout reproductive life. J Clin Invest (1975) 55:699. 
doi:10.1172/JCI107979 
11. Fehring RJ, Schneider M, Raviele K. Variability in the phases of the 
menstrual cycle. J Obstet Gynecol Neonatal Nurs (2006) 35:376–84. 
doi:10.1111/j.1552-6909.2006.00051.x 
12. Söderqvist G, Isaksson E, Von Schoultz B, Carlström K, Tani E, Skoog  L. 
Proliferation of breast epithelial cells in healthy women during the 
menstrual cycle. Am J Obstet Gynecol (1997) 176:123–8. doi:10.1016/
S0002-9378(97)80024-5 
13. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast 
tissue with menstrual cycle. Mod Pathol (2002) 15:1348–56. doi:10.1097/ 
01.MP.0000039566.20817.46 
14. Ferguson D, Anderson T. Morphological evaluation of cell turnover in 
relation to the menstrual cycle in the “resting” human breast. Br J Cancer 
(1981) 44:177. doi:10.1038/bjc.1981.168 
15. Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland 
is correlated with systemic levels of progesterone and not 17beta-estradiol 
during the estrous cycle. Biol Reprod (2001) 65:680–8. doi:10.1095/
biolreprod65.3.680 
16. Chua ACL, Hodson LJ, Moldenhauer LM, Robertson SA, Ingman WV. Dual 
roles for macrophages in ovarian cycle-associated development and remod-
elling of the mammary gland epithelium. Development (2010) 137:4229–38. 
doi:10.1242/dev.059261 
17. Hodson LJ, Chua AC, Evdokiou A, Robertson SA, Ingman WV. Macrophage 
phenotype in the mammary gland fluctuates over the course of the estrous 
cycle and is regulated by ovarian steroid hormones. Biol Reprod (2013) 89:65. 
doi:10.1095/biolreprod.113.109561 
18. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the 
epithelial estrogen receptor α is required for proliferation and morphogenesis 
in the mammary gland. Proc Natl Acad Sci U S A (2006) 103:2196–201. 
doi:10.1073/pnas.0510974103 
19. Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining 
a role in breast cancer. Expert Rev Endocrinol Metab (2011) 6:359–69. 
doi:10.1586/eem.11.25 
20. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer 
and atypia among young and middle-aged women: a study of 110 medicolegal 
autopsies. Br J Cancer (1987) 56:814–9. doi:10.1038/bjc.1987.296 
21. Medina D. Mammary developmental fate and breast cancer risk. Endocr Relat 
Cancer (2005) 12:483–95. doi:10.1677/erc.1.00804 
22. Gullino P, Pettigrew HM, Grantham F. N-nitrosomethylurea as mammary 
gland carcinogen in rats. J Natl Cancer Inst (1975) 54:401–14. 
23. Dao TL. The role of ovarian steroid hormones in mammary carcinogenesis. 
Horm Breast Cancer Banbury Rep (1981) (8):281–95. 
24. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. 
Environ Health Perspect (1996) 104:938–67. doi:10.1289/ehp.96104938 
25. Beatson GT. The treatment of cancer of the breast by oöphorectomy and 
thyroid extract. Br Med J (1901) 2:1145–8. 
26. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 
(2000) 21:427–33. doi:10.1093/carcin/21.3.427 
27. Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, et  al. The 
proliferative activity of mammary epithelial cells in normal tissue predicts 
breast cancer risk in premenopausal women. Cancer Res (2016) 76:1926–34. 
doi:10.1158/0008-5472.CAN-15-1927 
28. Nagasawa H, Yanai R, Taniguchi H. Importance of mammary gland DNA 
synthesis on carcinogen-induced mammary tumorigenesis in rats. Cancer 
Res (1976) 36:2223–6. 
29. Calaf GM. Susceptibility of human breast epithelial cells in vitro to hormones 
and drugs. Int J Oncol (2006) 28:285–95. doi:10.3892/ijo.28.2.285
30. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and 
caretakers. Nature (1997) 386(761):763. 
31. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and 
associations with cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 
11:1513–30. 
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
(2011) 144:646–74. doi:10.1016/j.cell.2011.02.013 
33. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens progestogens 
normal breast cell proliferation and breast cancer risk. Epidemiol Rev (1993) 
5:17–35. 
34. Brisken C, Hess K, Jeitziner R. Progesterone and overlooked endocrine 
pathways in breast cancer pathogenesis. Endocrinology (2015) 156:3442–50. 
doi:10.1210/en.2015-1392 
35. Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. 
Progesterone receptor modulates ER[agr] action in breast cancer. Nature 
(2015) 523:313–7. doi:10.1038/nature14583 
36. Rudland PS, Barraclough R, Fernig DG, Smith JA. 7 – mammary stem cells 
in normal development and cancer A2. In: Potten CS, editor. Stem Cells. 
London: Academic Press (1997). p. 147–232.
37. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the 
estrogen receptor. Trends Endocrinol Metab (2004) 15:193–7. doi:10.1016/ 
j.tem.2004.05.011 
9Atashgaran et al. Menstrual Cycle-Associated Breast Cancer Risk
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 267
38. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, et  al. 
Essential function of Wnt-4 in mammary gland development downstream 
of progesterone signaling. Genes Dev (2000) 14(6):650–4. doi:10.1101/
gad.14.6.650
39. Asselin-Labat M-L, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. 
Control of mammary stem cell function by steroid hormone signalling. 
Nature (2010) 465:798–802. doi:10.1038/nature09027 
40. Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CAM, Doxey DK, et al. 
Next-generation transcriptome sequencing of the premenopausal breast 
epithelium using specimens from a normal human breast tissue bank. Breast 
Cancer Res (2014) 16:1–16. doi:10.1186/bcr3627 
41. Simoes BM, Alferez DG, Howell SJ, Clarke RB. The role of steroid hor-
mones in breast cancer stem cells. Endocr Relat Cancer (2015) 22:T177–86. 
doi:10.1530/ERC-15-0350 
42. Clayton H, Titley I, Vivanco MD. Growth and differentiation of progenitor/
stem cells derived from the human mammary gland. Exp Cell Res (2004) 
297:444–60. doi:10.1016/j.yexcr.2004.03.029 
43. Graham JD, Mote PA, Salagame U, Van Dijk JH, Balleine RL, Huschtscha LI, 
et  al. DNA replication licensing and progenitor numbers are increased by 
progesterone in normal human breast. Endocrinology (2009) 150(7):3318–26. 
doi:10.1210/en.2008-1630 
44. Lombardi S, Honeth G, Ginestier C, Shinomiya I, Marlow R, Buchupalli B, 
et al. Growth hormone is secreted by normal breast epithelium upon proges-
terone stimulation and increases proliferation of stem/progenitor cells. Stem 
Cell Reports (2014) 2:780–93. doi:10.1016/j.stemcr.2014.05.005 
45. Visvader JE, Stingl J. Mammary stem cells and the differentiation hierarchy: 
current status and perspectives. Genes Dev (2014) 28:1143–58. doi:10.1101/
gad.242511.114 
46. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and 
carcinogenesis. Breast Cancer Res (2005) 7:86. doi:10.1186/bcr1021 
47. Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, 
Laudenschlager M, et al. Immune cell quantitation in normal breast tissue 
lobules with and without lobulitis. Breast Cancer Res Treat (2014) 144:539–49. 
doi:10.1007/s10549-014-2896-8 
48. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune 
hallmarks of cancer. Cancer Immunol Immunother (2011) 60:319–26. 
doi:10.1007/s00262-010-0968-0 
49. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: 
immunoselection and immunosubversion. Nat Rev Immunol (2006) 
6:715–27. doi:10.1038/nri1936 
50. Arruvito L, Sanz M, Banham AH, Fainboim L. Expansion of CD4+CD25+and 
FOXP3+ regulatory T cells during the follicular phase of the menstrual 
cycle: implications for human reproduction. J Immunol (2007) 178:2572–8. 
doi:10.4049/jimmunol.178.4.2572 
51. Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of 
human CD4+ CD25+ regulatory T cells by promoting their proliferation. 
Immunology (2006) 118:58–65. doi:10.1111/j.1365-2567.2006.02339.x 
52. Lee JH, Ulrich B, Cho J, Park J, Kim CH. Progesterone promotes differentiation 
of human cord blood fetal T cells into T regulatory cells but suppresses their 
differentiation into Th17 cells. J Immunol (2011) 187:1778–87. doi:10.4049/
jimmunol.1003919 
53. Khaled WT, Read EK, Nicholson SE, Baxter FO, Brennan AJ, Came PJ, 
et al. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary 
epithelial cell development. Development (2007) 134:2739–50. doi:10.1242/
dev.003194 
54. Routley CE, Ashcroft GS. Effect of estrogen and progesterone on macrophage 
activation during wound healing. Wound Repair Regen (2009) 17:42–50. 
doi:10.1111/j.1524-475X.2008.00440.x 
55. Arck P, Hansen PJ, Mulac Jericevic B, Piccinni MP, Szekeres-Bartho 
J. Progesterone during pregnancy: endocrine-immune cross talk in mamma-
lian species and the role of stress. Am J Reprod Immunol (2007) 58:268–79. 
doi:10.1111/j.1600-0897.2007.00512.x 
56. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and func-
tion of tumor-associated macrophages. Immunol Today (1992) 13:265–70. 
doi:10.1016/0167-5699(92)90008-U 
57. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 
cytokine production by peripheral blood mononuclear cells as a parameter 
of immunological dysfunction in advanced cancer patients. Cancer Immunol 
Immunother (1999) 48:435–42. doi:10.1007/s002620050620 
58. Dasari P, Sharkey DJ, Noordin E, Glynn DJ, Hodson LJ, Chin PY, et  al. 
Hormonal regulation of the cytokine microenvironment in the mammary 
gland. J Reprod Immunol (2014) 106:58–66. doi:10.1016/j.jri.2014.07.002 
59. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. 
Endocr Rev (1997) 18:502–19. doi:10.1210/edrv.18.4.0308 
60. Ratko TA, Beattie CW. Estrous cycle modification of rat mammary tumor 
induction by a single dose of N-methyl-N-nitrosourea. Cancer Res (1985) 
45:3042–7. 
61. Braun RJ, Pezzuto JM, Anderson CH, Beattie CW. Estrous cycle status alters 
N-methyl-N-nitrosourea (NMU)-induced rat mammary tumor growth 
and regression. Cancer Lett (1989) 48:205–11. doi:10.1016/0304-3835(89) 
90119-5 
62. Sun X, Robertson SA, Ingman WV. Regulation of epithelial cell turnover 
and macrophage phenotype by epithelial cell-derived transforming growth 
factor beta1 in the mammary gland. Cytokine (2013) 61:377–88. doi:10.1016/ 
j.cyto.2012.12.002 
63. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. 
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with 
macrophages is due to TNF-α dependent up-regulation of matrix metallo-
proteases. Carcinogenesis (2004) 25:1543–9. doi:10.1093/carcin/bgh146 
64. Fleming JM, Miller TC, Kidacki M, Ginsburg E, Stuelten CH, Stewart DA, 
et  al. Paracrine interactions between primary human macrophages and 
human fibroblasts enhance murine mammary gland humanization in vivo. 
Breast Cancer Res (2012) 14:R97. doi:10.1186/bcr3215 
65. Brady NJ, Chuntova P, Schwertfeger KL. Macrophages: regulators of the inflam-
matory microenvironment during mammary gland development and breast 
cancer. Mediators Inflamm (2016) 2016:4549676. doi:10.1155/2016/4549676 
66. Moses H, Barcellos-Hoff MH. TGF-β biology in mammary development and 
breast cancer. Cold Spring Harb Perspect Biol (2011) 3:a003277. doi:10.1101/
cshperspect.a003277 
67. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 
(2007) 35:495–516. doi:10.1080/01926230701320337 
68. Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeo-
stasis. Nat Immunol (2015) 16:907–17. doi:10.1038/ni.3253 
69. Gelebart P, Opas M, Michalak M. Calreticulin, a Ca2+-binding chaperone 
of the endoplasmic reticulum. Int J Biochem Cell Biol (2005) 37:260–6. 
doi:10.1016/j.biocel.2004.02.030 
70. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele 
P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 
(2012) 12:860–75. doi:10.1038/nrc3380 
71. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic 
cells: getting rid of the corpses. Mol Cell (2004) 14:277–87. doi:10.1016/
S1097-2765(04)00237-0 
72. Gardai SJ, Mcphillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-
Ullrich JE, et  al. Cell-surface calreticulin initiates clearance of viable or 
apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 
123:321–34. doi:10.1016/j.cell.2005.08.032 
73. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/
necrotic cell clearance. Cell Death Differ (2010) 17:381–97. doi:10.1038/
cdd.2009.195 
74. Monks J, Rosner D, Jon Geske F, Lehman L, Hanson L, Neville MC, et al. 
Epithelial cells as phagocytes: apoptotic epithelial cells are engulfed by mam-
mary alveolar epithelial cells and repress inflammatory mediator release. Cell 
Death Differ (2005) 12:107–14. doi:10.1038/sj.cdd.4401517 
75. Mukherjee A, Soyal SM, Li J, Ying Y, He B, Demayo FJ, et al. Targeting RANKL 
to a specific subset of murine mammary epithelial cells induces ordered 
branching morphogenesis and alveologenesis in the absence of progesterone 
receptor expression. FASEB J (2010) 24:4408–19. doi:10.1096/fj.10-157982 
76. Fernandez-Valdivia R, Lydon JP. From the ranks of mammary proges-
terone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2012) 
357:91–100. doi:10.1016/j.mce.2011.09.030 
77. Hu H, Wang J, Gupta A, Shidfar A, Branstetter D, Lee O, et  al. RANKL 
expression in normal and malignant breast tissue responds to progesterone 
and is up-regulated during the luteal phase. Breast Cancer Res Treat (2014) 
146:515–23. doi:10.1007/s10549-014-3049-9 
10
Atashgaran et al. Menstrual Cycle-Associated Breast Cancer Risk
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 267
78. Brisken C. Progesterone signalling in breast cancer: a neglected hormone 
coming into the limelight. Nat Rev Cancer (2013) 13:385–96. doi:10.1038/
nrc3518 
79. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye J-F, 
et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci 
Transl Med (2013) 5:182ra155. doi:10.1126/scitranslmed.3005654 
80. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene 
and 5alpha-pregnane progesterone metabolites formed in nontumorous and 
tumorous breast tissue have opposite effects on breast cell proliferation and 
adhesion. Cancer Res (2000) 60:936–43. 
81. Ferguson JE, Schor AM, Howell A, Ferguson MW. Changes in the extracellu-
lar matrix of the normal human breast during the menstrual cycle. Cell Tissue 
Res (1992) 268:167–77. doi:10.1007/BF00338066 
82. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche 
in cancer progression. J Cell Biol (2012) 196:395–406. doi:10.1083/jcb. 
201102147 
83. Hallberg G, Andersson E, Naessen T, Ordeberg GE. The expression of 
syndecan-1, syndecan-4 and decorin in healthy human breast tissue during 
the menstrual cycle. Reprod Biol Endocrinol (2010) 8:35. doi:10.1186/ 
1477-7827-8-35 
84. Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee 
S, Rotunno M, et  al. Pathway analysis of breast cancer genome-wide 
association study highlights three pathways and one canonical sig-
naling cascade. Cancer Res (2010) 70:4453–9. doi:10.1158/0008-5472.
CAN-09-4502 
85. Okolicsanyi RK, Buffiere A, Jacinto JM, Chacon-Cortes D, Chambers 
SK, Youl PH, et  al. Association of heparan sulfate proteoglycans SDC1 
and SDC4 polymorphisms with breast cancer in an Australian Caucasian 
population. Tumour Biol (2015) 36:1731–8. doi:10.1007/s13277-014- 
2774-3 
86. Baba F, Swartz K, Van Buren R, Eickhoff J, Zhang Y, Wolberg W, 
et  al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen 
 receptor-negative, highly proliferative breast carcinoma subtype. Breast 
Cancer Res Treat (2006) 98:91–8. doi:10.1007/s10549-005-9135-2 
87. Oda G, Sato T, Ishikawa T, Kawachi H, Nakagawa T, Kuwayama T, et  al. 
Significance of stromal decorin expression during the progression of breast 
cancer. Oncol Rep (2012) 28:2003–8. doi:10.3892/or.2012.2040 
88. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. 
Reduced expression of the small leucine-rich proteoglycans, lumican, and 
decorin is associated with poor outcome in node-negative invasive breast 
cancer. Clin Cancer Res (2003) 9:207–14. 
89. Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, et al. 
Insights into the key roles of proteoglycans in breast cancer biology and trans-
lational medicine. Biochim Biophys Acta (2015) 1855:276–300. doi:10.1016/ 
j.bbcan.2015.03.006 
90. Dabrosin C. Variability of vascular endothelial growth factor in normal 
human breast tissue in  vivo during the menstrual cycle. J Clin Endocrinol 
Metab (2003) 88:2695–8. doi:10.1210/jc.2002-021584 
91. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. 
Vasc Health Risk Manag (2006) 2:213–9. doi:10.2147/vhrm.2006.2.3.213 
92. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. 
Physiology (Bethesda) (2010) 25:85–101. doi:10.1152/physiol.00045.2009 
93. Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of 
vascular endothelial growth factor in human breast cancer cells: preferential 
regulation by progesterone receptor B. Cancer Res (2004) 64:2238–44. 
doi:10.1158/0008-5472.CAN-03-3044 
94. Hyder SM. Sex-steroid regulation of vascular endothelial growth factor in 
breast cancer. Endocr Relat Cancer (2006) 13:667–87. doi:10.1677/erc.1.00931 
95. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemi-
ologic and experimental evidence and potential mechanisms. JAMA (2001) 
286:2143–51. doi:10.1001/jama.286.17.2143 
96. Dumitrescu RG, Shields PG. The etiology of alcohol-induced breast cancer. 
Alcohol (2005) 35:213–25. doi:10.1016/j.alcohol.2005.04.005 
97. Hendrick RE. Radiation doses and cancer risks from breast imaging Studies 
1. Radiology (2010) 257:246–53. doi:10.1148/radiol.10100570 
98. Smith-Bindman R. Environmental causes of breast cancer and radiation from 
medical imaging: findings from the Institute of Medicine report. Arch Intern 
Med (2012) 172:1023–7. doi:10.1001/archinternmed.2012.2329 
99. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella  I, 
et  al. Immune approaches to the treatment of breast cancer, around the 
corner? Breast Cancer Res (2014) 16:1. doi:10.1186/bcr3620 
100. Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C. Immunology and breast 
cancer: toward a new way of understanding breast cancer and developing 
novel therapeutic strategies. Immunology (2015) 13(6):372–82. 
101. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et  al. 
Molecular portraits of human breast tumours. Nature (2000) 406:747–52. 
doi:10.1038/35021093 
102. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et  al. 
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin 
Oncol (2009) 27:1160–7. doi:10.1200/JCO.2008.18.1370 
103. Bernhardt SM, Dasari P, Walsh D, Townsend AR, Price TJ, Ingman WV. 
Hormonal modulation of breast cancer gene expression: implications for 
intrinsic subtyping in premenopausal women. Front Oncol (2016) 6:241. 
doi:10.3389/fonc.2016.00241
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Atashgaran, Wrin, Barry, Dasari and Ingman. This is an open-ac-
cess article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
